[Multicenter open study with docetaxel. Treatment of patients with locally advanced or metastatic breast carcinoma]

Autor:	Campos O, Gonçalves I, Furtado I, Espírito Santo J, Alcazar A, Pinguinha A, Fráguas A, Chumbo M, Mj, Cunha, Antonio Oliveira
Předmět:	Adult Paclitaxel Humans Breast Neoplasms Female Taxoids Docetaxel Middle Aged Neoplasm Metastasis Antineoplastic Agents Phytogenic Aged Neoplasm Staging
Zdroj:	Europe PubMed Central Acta Médica Portuguesa; v. 14, n. 4 (2001): Julho-Agosto; 375-80 Repositório Científico de Acesso Aberto de Portugal Repositório Científico de Acesso Aberto de Portugal (RCAAP) instacron:RCAAP
ISSN:	1646-0758 0870-399X
Popis:	The efficacy and safety of docetaxel were evaluated in an open, multicentric, non comparative study involving 24 patients with locally advanced or metastatic breast cancer, eligible for second line or subsequent anticancer chemotherapy; the results confirm a global response around 50%, suggesting some advantages when compared to the usual treatments in this set of patients; the median duration of response, the median time to progression and the median time of survival were respectively, 309, 219 and 345 days; the main iatrogenic event was haematological, mainly in the white and red blood cells.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1b53ba120822765cc8ba08d83b4fd03c http://europepmc.org/abstract/med/11762177 Zobrazit plný text záznamu